Inovio Pharmaceuticals - INO Stock Forecast, Price & News

Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids. The company engages in conducting and planning clinical studies of its DNA medicines for HPV-associated precancers, including cervical, vulvar, and anal dysplasia; HPV-associated cancers, such as head and neck, cervical, anal, penile, vulvar, and vaginal; other HPV-associated disorders, including recurrent respiratory papillomatosis; glioblastoma multiforme; prostate cancer; HIV; Ebola; Middle East Respiratory Syndrome (MERS); and Lassa fever. Its partners and collaborators include ApolloBio Corp., AstraZeneca, Beijing Advaccine Biotechnology Co., Ltd., The Bill & Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations (CEPI), Defense Advanced Research Projects Agency (DARPA), Department of Defense (DoD), HIV Vaccines Trial Network, International Vaccine Institute, Kaneka Eurogentec, Medical CBRN Defense Consortium (MCDC), National Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Ology Bioservices, the Parker Institute for Cancer Immunotherapy, Plumbline Life Sciences, Regeneron Pharmaceuticals, Thermo Fisher Scientific, University of Pennsylvania, Walter Reed Army Institute of Research, and The Wistar Institute. The company has an agreement with Richter-Helm BioLogics GmbH & Co. KG to support investigational DNA vaccine INO-4800 for COVID-19; and a partnership with International Vaccine Institute and Seoul National University Hospital. The company was founded in 1979 and is headquartered in Plymouth Meeting, Pennsylvania.

Inovio Pharmaceuticals Trading Up 1.9 %

Shares of INO Stock traded up $0.05 during trading hours on Monday, hitting $2.68. The company had a trading volume of 98,134 shares, compared to its average volume of 5,686,627. Inovio Pharmaceuticals has a 12 month low of $1.38 and a 12 month high of $9.74. The firm's fifty day moving average is $1.96 and its 200 day moving average is $2.66. The company has a current ratio of 3.18, a quick ratio of 3.18 and a debt-to-equity ratio of 0.06.

Inovio Pharmaceuticals (NASDAQ:INO - Get Rating) last announced its earnings results on Tuesday, August 9th. The biopharmaceutical company reported ($0.46) EPS for the quarter, missing the consensus estimate of ($0.28) by ($0.18). The business had revenue of $0.78 million during the quarter, compared to analyst estimates of $0.52 million. Inovio Pharmaceuticals had a negative return on equity of 94.19% and a negative net margin of 16,775.78%. The firm's revenue was up 187.5% compared to the same quarter last year. During the same period in the previous year, the firm earned ($0.39) earnings per share. As a group, equities research analysts forecast that Inovio Pharmaceuticals will post -1.31 EPS for the current year.

Wall Street Analyst Weigh In

Several equities analysts recently weighed in on INO shares. Oppenheimer cut Inovio Pharmaceuticals from an "outperform" rating to a "market perform" rating in a research report on Wednesday, May 11th. Royal Bank of Canada started coverage on Inovio Pharmaceuticals in a research report on Tuesday, July 19th. They set a "sector perform" rating and a $4.00 price objective for the company. Cantor Fitzgerald cut their price objective on Inovio Pharmaceuticals from $6.00 to $3.00 in a research report on Wednesday, May 11th. Finally, StockNews.com upgraded Inovio Pharmaceuticals to a "sell" rating in a research note on Monday, May 23rd. One equities research analyst has rated the stock with a sell rating and five have given a hold rating to the company's stock. According to MarketBeat.com, Inovio Pharmaceuticals presently has an average rating of "Hold" and a consensus target price of $5.75.

Insider Transactions at Inovio Pharmaceuticals

In other Inovio Pharmaceuticals news, Director David B. Weiner sold 11,875 shares of the company's stock in a transaction on Thursday, August 11th. The stock was sold at an average price of $2.66, for a total transaction of $31,587.50. Following the transaction, the director now owns 892,625 shares of the company's stock, valued at approximately $2,374,382.50. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. 3.30% of the stock is owned by company insiders.